欧洲皮肤病与性病学会更新寻常型与落叶型天疱疮S2K管理指南
欧洲皮肤病与性病学会(EADV)自身免疫性大疱病工作组对天疱疮管理指南进行全面更新,纳入工作组全体成员同意程度,最终版本获欧洲皮肤病论坛(EDF)及多个患者组织认可。指南指出天疱疮为危及生命的自身免疫性大疱病,随机对照试验有限,利妥昔单抗已在欧洲和美国获批为中重度寻常型天疱疮一线治疗。
要点
- 天疱疮为危及生命的自身免疫性大疱病,以黏膜和皮肤水疱、糜烂为特征。
- 利妥昔单抗已在欧洲和美国获批为中重度寻常型天疱疮一线治疗。
- 指南由EADV工作组更新,纳入成员同意程度,获EDF和患者组织认可。
核心结论
- 天疱疮管理指南已全面更新,最终版本获欧洲皮肤病论坛和多个患者组织认可。
研究设计与样本
- 欧洲皮肤病与性病学会(EADV)自身免疫性大疱病工作组发起的指南更新,纳入工作组全体成员同意程度。
主要发现
- 天疱疮是一组危及生命的自身免疫性大疱病,以黏膜和皮肤水疱、糜烂为特征。
- 在免疫抑制治疗时代之前,天疱疮几乎总是致命的。
- 由于疾病罕见,仅有的随机对照治疗试验很少。
- 利妥昔单抗已在欧洲和美国获批为中重度寻常型天疱疮一线治疗。
关键数值与推荐
- 利妥昔单抗已获批为中重度寻常型天疱疮一线治疗(欧洲和美国)。
局限性
- 由于天疱疮罕见,仅有的随机对照治疗试验很少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pemphigus encompasses a group of life-threatening autoimmune bullous diseases characterized by blisters and erosions of the mucous membranes and skin. Before the era of immunosuppressive treatment, pemphigus was almost always fatal. Due to its rarity, only few randomized controlled therapeutic trials are available. Recently, rituximab has been approved as first-line treatment for moderate and severe pemphigus vulgaris in Europe and the United States. OBJECTIVES: The Autoimmune blistering diseases Task Force of the European Academy of Dermatology and Venereology (EADV) has initiated a throughout update of the guideline for the management of patients with pemphigus. RESULTS: The guidelines for the management of pemphigus were updated, and the degree of consent among all task force members was included. The final version of the guideline was consented by the European Dermatology Forum (EDF) and several patient organizations.
引用
- Joly P, Horvath B, Patsatsi Α, et al. Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV). J Eur Acad Dermatol Venereol. 2020. PMID: 32830877. doi:10.1111/jdv.16752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。